Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.

Rossi A, Roberto M, Panebianco M, Botticelli A, Mazzuca F, Marchetti P.

Eur J Pharmacol. 2019 Aug 22;862:172621. doi: 10.1016/j.ejphar.2019.172621. [Epub ahead of print] Review.

2.

Clinical Impact of Highly Purified, Whey Proteins in Patients Affected With Colorectal Cancer Undergoing Chemotherapy: Preliminary Results of a Placebo-Controlled Study.

Mazzuca F, Roberto M, Arrivi G, Sarfati E, Schipilliti FM, Crimini E, Botticelli A, Di Girolamo M, Muscaritoli M, Marchetti P.

Integr Cancer Ther. 2019 Jan-Dec;18:1534735419866920. doi: 10.1177/1534735419866920.

3.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.

Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P.

Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32583. [Epub ahead of print]

PMID:
31330065
4.

Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors.

Giusti R, Scarpi E, Cannita K, Silva RR, Filetti M, Mazzotta M, Ficorella C, Botticelli A, Maltoni M, Marchetti P, Porzio G, Verna L.

Support Care Cancer. 2019 Jun 8. doi: 10.1007/s00520-019-04905-y. [Epub ahead of print]

PMID:
31177390
5.

Electrochemotherapy as Promising Treatment Option in Rare Recurrent Cutaneous Neoplasm of the Scalp: Case Report of an Elderly Patient.

Crimini E, Roberto M, Degli Effetti V, Marchetti P, Botticelli A, Schipilliti FM, Arrivi G, Mazzuca F.

Case Rep Oncol Med. 2019 Mar 28;2019:2507642. doi: 10.1155/2019/2507642. eCollection 2019.

6.

CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy.

Sacchetti B, Botticelli A, Pierelli L, Nuti M, Alimandi M.

Int J Mol Sci. 2019 Apr 17;20(8). pii: E1903. doi: 10.3390/ijms20081903. Review.

7.

Impact of tumor site on the prognosis of small bowel adenocarcinoma.

Falcone R, Romiti A, Filetti M, Roberto M, Righini R, Botticelli A, Pilozzi E, Ghidini M, Pizzo C, Mazzuca F, Marchetti P.

Tumori. 2019 Apr 1:300891619839297. doi: 10.1177/0300891619839297. [Epub ahead of print]

PMID:
30935289
8.

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.

Botticelli A, Salati M, Di Pietro FR, Strigari L, Cerbelli B, Zizzari IG, Giusti R, Mazzotta M, Mazzuca F, Roberto M, Vici P, Pizzuti L, Nuti M, Marchetti P.

J Transl Med. 2019 Mar 27;17(1):99. doi: 10.1186/s12967-019-1847-x.

9.

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable.

Cortellini A, Bersanelli M, Buti S, Cannita K, Santini D, Perrone F, Giusti R, Tiseo M, Michiara M, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Rastelli F, Pergolesi F, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, De Giglio A, Iacono D, Gelibter A, Occhipinti MA, Parisi A, Porzio G, Fargnoli MC, Ascierto PA, Ficorella C, Natoli C.

J Immunother Cancer. 2019 Feb 27;7(1):57. doi: 10.1186/s40425-019-0527-y.

10.

Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.

Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, Tinari N, De Tursi M, Zoratto F, Veltri E, Marconcini R, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Botticelli A, Antonini Cappellini GC, De Galitiis F, Vitale MG, Sabbatini R, Bracarda S, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Chiari R, Ricciuti B, Iacono D, Migliorino MR, Rossi A, Porzio G, Cannita K, Ciciarelli V, Fargnoli MC, Ascierto PA, Ficorella C.

Oncologist. 2019 Jun;24(6):e327-e337. doi: 10.1634/theoncologist.2018-0618. Epub 2019 Feb 22.

PMID:
30796151
11.

Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation?

Cerbelli B, Botticelli A, Pisano A, Campagna D, De Vincentiis L, Pernazza A, Frusone F, Scavina P, Monti M, Fortunato L, Costarelli L, d'Amati G.

Breast J. 2019 Mar;25(2):273-277. doi: 10.1111/tbj.13206. Epub 2019 Feb 7.

PMID:
30734420
12.

Biliary tract cancer: current challenges and future prospects.

Ghidini M, Pizzo C, Botticelli A, Hahne JC, Passalacqua R, Tomasello G, Petrelli F.

Cancer Manag Res. 2018 Dec 28;11:379-388. doi: 10.2147/CMAR.S157156. eCollection 2019. Review.

13.

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Airoldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, Vici P.

J Cell Physiol. 2019 Jun;234(6):7708-7717. doi: 10.1002/jcp.27832. Epub 2018 Dec 10.

PMID:
30536609
14.

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study.

Gamucci T, Pizzuti L, Natoli C, Mentuccia L, Sperduti I, Barba M, Sergi D, Iezzi L, Maugeri-Saccà M, Vaccaro A, Magnolfi E, Gelibter A, Barchiesi G, Magri V, D'Onofrio L, Cassano A, Rossi E, Botticelli A, Moscetti L, Omarini C, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Mazzotta M, Bria E, Foglietta J, Samaritani R, Garufi C, Mariani L, Barni S, Mirabelli R, Sarmiento R, Graziano V, Santini D, Marchetti P, Tonini G, Di Lauro L, Sanguineti G, Paoletti G, Tomao S, De Maria R, Veltri E, Paris I, Giotta F, Latorre A, Giordano A, Ciliberto G, Vici P.

Cancer Biol Ther. 2019;20(2):192-200. doi: 10.1080/15384047.2018.1523095. Epub 2018 Nov 7.

15.

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?

Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, Federica M, Simmaco M, Nuti M, Marchetti P.

J Transl Med. 2018 Aug 6;16(1):219. doi: 10.1186/s12967-018-1595-3.

16.

The ambitious role of anti angiogenesis molecules: Turning a cold tumor into a hot one.

Nuti M, Zizzari IG, Botticelli A, Rughetti A, Marchetti P.

Cancer Treat Rev. 2018 Nov;70:41-46. doi: 10.1016/j.ctrv.2018.07.016. Epub 2018 Jul 26. Review.

17.

Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival.

Roberto M, Botticelli A, Strigari L, Ghidini M, Onesti CE, Ratti M, Benzoni I, Pizzo C, Falcone R, Lomiento D, Donida BM, Totaro L, Mazzuca F, Marchetti P.

Med Oncol. 2018 Jun 19;35(7):111. doi: 10.1007/s12032-018-1166-8.

PMID:
29923032
18.

Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines.

Mazzuca F, Onesti CE, Roberto M, Di Girolamo M, Botticelli A, Begini P, Strigari L, Marchetti P, Muscaritoli M.

Oncotarget. 2018 May 22;9(39):25714-25722. doi: 10.18632/oncotarget.25394. eCollection 2018 May 22.

19.

Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution.

Salati M, Baldessari C, Cerbelli B, Botticelli A.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S91-S94. doi: 10.21037/tlcr.2018.01.14. No abstract available.

20.

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway.

Zizzari IG, Napoletano C, Botticelli A, Caponnetto S, Calabrò F, Gelibter A, Rughetti A, Ruscito I, Rahimi H, Rossi E, Schinzari G, Marchetti P, Nuti M.

Cancer Immunol Res. 2018 Jun;6(6):711-722. doi: 10.1158/2326-6066.CIR-17-0594. Epub 2018 Apr 26.

21.

Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical Practice.

Milano A, Mazzetta F, Valente S, Ranieri D, Leone L, Botticelli A, Onesti CE, Lauro S, Raffa S, Torrisi MR, Marchetti P.

Anal Cell Pathol (Amst). 2018 Feb 27;2018:3506874. doi: 10.1155/2018/3506874. eCollection 2018.

22.

PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?

Cerbelli B, Pernazza A, Botticelli A, Fortunato L, Monti M, Sciattella P, Campagna D, Mazzuca F, Mauri M, Naso G, Marchetti P, d'Amati G, Costarelli L.

Biomed Res Int. 2017;2017:1750925. doi: 10.1155/2017/1750925. Epub 2017 Dec 14.

23.

Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab.

Pizzuti L, Sergi D, Sperduti I, Lauro LD, Mazzotta M, Botti C, Izzo F, Marchetti L, Tomao S, Marchetti P, Natoli C, Grassadonia A, Gamucci T, Mentuccia L, Magnolfi E, Vaccaro A, Cassano A, Rossi E, Botticelli A, Sini V, Sarobba MG, Fabbri MA, Moscetti L, Astone A, Michelotti A, De Angelis C, Bertolini I, Angelini F, Ciliberto G, Maugeri-Saccà M, Giordano A, Barba M, Vici P.

Cancer Biol Ther. 2018 Apr 3;19(4):328-334. doi: 10.1080/15384047.2017.1416938. Epub 2018 Feb 16.

24.

The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: Clinical case report of a long-responder patient treated with regorafenib beyond progression.

Roberto M, Falcone R, Mazzuca F, Archibugi L, Castaldi N, Botticelli A, Osti MF, Marchetti P.

Medicine (Baltimore). 2017 Dec;96(48):e9023. doi: 10.1097/MD.0000000000009023.

25.

Crizotinib plus radiotherapy in brain oligoprogressive NSCLC ROS1 rearranged and PD-L1 strong.

Occhipinti M, Falcone R, Onesti CE, Botticelli A, Mazzuca F, Marchetti P, Lauro S.

J Thorac Dis. 2017 Nov;9(11):E985-E989. doi: 10.21037/jtd.2017.09.74.

26.

The sexist behaviour of immune checkpoint inhibitors in cancer therapy?

Botticelli A, Onesti CE, Zizzari I, Cerbelli B, Sciattella P, Occhipinti M, Roberto M, Di Pietro F, Bonifacino A, Ghidini M, Vici P, Pizzuti L, Napoletano C, Strigari L, D'Amati G, Mazzuca F, Nuti M, Marchetti P.

Oncotarget. 2017 Nov 1;8(59):99336-99346. doi: 10.18632/oncotarget.22242. eCollection 2017 Nov 21.

27.

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.

Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T.

Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.

28.

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study.

Pizzuti L, Marchetti P, Natoli C, Gamucci T, Santini D, Scinto AF, Iezzi L, Mentuccia L, D'Onofrio L, Botticelli A, Moscetti L, Sperati F, Botti C, Ferranti F, Buglioni S, Sanguineti G, Di Filippo S, di Lauro L, Sergi D, Catenaro T, Tomao S, Giordano A, Maugeri-Saccà M, Barba M, Vici P.

Sci Rep. 2017 Sep 6;7(1):10597. doi: 10.1038/s41598-017-10061-2.

29.

Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.

Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P.

J Cell Physiol. 2018 Mar;233(3):2313-2323. doi: 10.1002/jcp.26103. Epub 2017 Sep 27.

PMID:
28710865
30.

Adjuvant chemotherapy for resected biliary tract cancers: a systematic review and meta-analysis.

Ghidini M, Tomasello G, Botticelli A, Barni S, Zabbialini G, Seghezzi S, Passalacqua R, Braconi C, Petrelli F.

HPB (Oxford). 2017 Sep;19(9):741-748. doi: 10.1016/j.hpb.2017.05.010. Epub 2017 Jul 3. Review.

31.

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.

Sini V, Botticelli A, Lunardi G, Gori S, Marchetti P.

Pharmacogenomics. 2017 Jun;18(8):821-830. doi: 10.2217/pgs-2017-0006. Epub 2017 Jun 8. Review.

PMID:
28592202
32.

Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.

Angelini S, Botticelli A, Onesti CE, Giusti R, Sini V, Durante V, Strigari L, Gentile G, Cerbelli B, Pellegrini P, Sgroi V, Occhipinti M, DI Pietro FR, Rossi A, Simmaco M, Mazzuca F, Marchetti P.

Anticancer Res. 2017 May;37(5):2633-2639.

PMID:
28476838
33.

A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.

Botticelli A, Onesti CE, Strigari L, Occhipinti M, Di Pietro FR, Cerbelli B, Petremolo A, Anselmi E, Macrini S, Roberto M, Falcone R, Lionetto L, Borro M, Milano A, Gentile G, Simmaco M, Marchetti P, Mazzuca F.

Anticancer Drugs. 2017 Jun;28(5):551-556. doi: 10.1097/CAD.0000000000000492.

PMID:
28296649
34.

Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.

Roberto M, Romiti A, Botticelli A, Mazzuca F, Lionetto L, Gentile G, Paris I, Falcone R, Bassanelli M, Di Pietro FR, Onesti CE, Anselmi E, Macrini S, Simmaco M, Marchetti P.

Eur J Clin Pharmacol. 2017 Feb;73(2):157-164. doi: 10.1007/s00228-016-2160-8. Epub 2016 Nov 18.

PMID:
27864592
35.

5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.

Onesti CE, Botticelli A, La Torre M, Borro M, Gentile G, Romiti A, Lionetto L, Petremolo A, Occhipinti M, Roberto M, Falcone R, Simmaco M, Marchetti P, Mazzuca F.

Anticancer Drugs. 2017 Mar;28(3):322-326. doi: 10.1097/CAD.0000000000000453.

PMID:
27845948
36.

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.

Botticelli A, Zizzari I, Mazzuca F, Ascierto PA, Putignani L, Marchetti L, Napoletano C, Nuti M, Marchetti P.

Oncotarget. 2017 Jan 31;8(5):8890-8899. doi: 10.18632/oncotarget.12985. Review.

37.

Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer.

Borro M, Botticelli A, Mazzuca F, Onesti EC, Gentile G, Romiti A, Cerbelli B, Mazzotti E, Marchetti L, Lionetto L, Simmaco M, Marchetti P.

Oncotarget. 2017 Feb 21;8(8):14050-14057. doi: 10.18632/oncotarget.12571.

38.

Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?

Botticelli A, Borro M, Onesti CE, Strigari L, Gentile G, Cerbelli B, Romiti A, Occhipinti M, Sebastiani C, Lionetto L, Marchetti L, Simmaco M, Marchetti P, Mazzuca F.

PLoS One. 2016 Sep 22;11(9):e0163105. doi: 10.1371/journal.pone.0163105. eCollection 2016.

39.

The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer.

Romiti A, Roberto M, D'Antonio C, Onesti CE, Barucca V, Milano A, Gentile G, Lionetto L, Medda E, Mazzuca F, Botticelli A, Falcone R, Simmaco M, Marchetti P.

Anticancer Drugs. 2016 Nov;27(10):1044-9. doi: 10.1097/CAD.0000000000000429.

PMID:
27557140
40.

CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy.

Mazzuca F, Botticelli A, Mazzotti E, La Torre M, Borro M, Marchetti L, Maddalena C, Gentile G, Simmaco M, Marchetti P.

Eurasian J Med. 2016 Feb;48(1):10-4. doi: 10.5152/eurasianjmed.2015.008. Epub 2015 Jul 7.

41.

Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.

Mazzuca F, Borro M, Botticelli A, Mazzotti E, Marchetti L, Gentile G, La Torre M, Lionetto L, Simmaco M, Marchetti P.

Oncotarget. 2016 Apr 12;7(15):20612-20. doi: 10.18632/oncotarget.7991.

42.

Positive impact of elastography in breast cancer diagnosis: an institutional experience.

Botticelli A, Mazzotti E, Di Stefano D, Petrocelli V, Mazzuca F, La Torre M, Ciabatta FR, Giovagnoli RM, Marchetti P, Bonifacino A.

J Ultrasound. 2015 Aug 12;18(4):321-7. doi: 10.1007/s40477-015-0177-y. eCollection 2015 Dec.

43.

FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?

Botticelli A, Mazzuca F, Borro M, Mazzotti E, La Torre M, Bonifacino A, Ciabatta FR, Gentile G, Maddalena C, Simmaco M, Marchetti P.

World J Oncol. 2015 Oct;6(5):437-440. doi: 10.14740/wjon934w. Epub 2015 Oct 26.

44.

Effect of MTHFR Polymorphisms on Gastrointestinal Cancer Risk in Italy.

Mazzuca F, Borro M, Botticelli A, Aimati L, Gentile G, Capalbo C, Maddalena C, Mazzotti E, Simmaco M, Marchetti P.

World J Oncol. 2015 Aug;6(4):394-397. doi: 10.14740/wjon930w. Epub 2015 Aug 27.

45.

Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction.

Gentile G, Botticelli A, Lionetto L, Mazzuca F, Simmaco M, Marchetti P, Borro M.

Pharmacogenomics J. 2016 Aug;16(4):320-5. doi: 10.1038/tpj.2015.56. Epub 2015 Jul 28.

PMID:
26216193
46.

Electrochemotherapy treatment of cutaneous metastases from breast cancer.

Mercantini P, Lorenzon L, Tarantino G, Balducci G, Ferri M, Mazzuca F, Botticelli A, Marchetti P.

Am Surg. 2015 May;81(5):E222-5. No abstract available.

PMID:
25975317
47.

Standard versus limited colon resection for high risk T1 colon cancer. A matched case-control study.

La Torre M, Nigri G, Mazzuca F, Ferri M, Botticelli A, Lorenzon L, Pilozzi E, Ziparo V.

J Gastrointestin Liver Dis. 2014 Sep;23(3):285-90. doi: 10.15403/jgld.2014.1121.233.mlt.

48.

Breast metastasis from clear cell renal cell carcinoma.

Botticelli A, De Francesco GP, Di Stefano D.

J Ultrasound. 2013 Jul 5;16(3):127-30. doi: 10.1007/s40477-013-0026-9. eCollection 2013 Jul 5.

49.

Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways.

Giuliani D, Bitto A, Galantucci M, Zaffe D, Ottani A, Irrera N, Neri L, Cavallini GM, Altavilla D, Botticelli AR, Squadrito F, Guarini S.

Neurobiol Aging. 2014 Mar;35(3):537-47. doi: 10.1016/j.neurobiolaging.2013.08.030. Epub 2013 Oct 1.

PMID:
24094579
50.

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.

Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E.

Clinicoecon Outcomes Res. 2013 Apr 11;5:125-35. doi: 10.2147/CEOR.S41850. Print 2013.

Supplemental Content

Loading ...
Support Center